Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Related Articles by Review for PubMed (Select 18852532)

3.

Vitamin D analogues for the management of secondary hyperparathyroidism.

Martin KJ, González EA.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34-40. Review.

PMID:
11689385
4.

Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.

Schömig M, Ritz E.

Nephrol Dial Transplant. 2000;15 Suppl 5:18-24. Review.

5.

[Serum calcium concentration and the safety of vitamin D therapy].

Ikeda Y, Takemoto F.

Clin Calcium. 2004 Sep;14(9):79-82. Review. Japanese.

PMID:
15577116
6.

Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM.

Endocr Pract. 2008 Jan-Feb;14(1):18-27. Review.

PMID:
18238737
7.

Recent advances in our understanding of the vitamin D endocrine system.

De Luca HF.

J Lab Clin Med. 1976 Jan;87(1):7-26. Review.

PMID:
173767
8.

1alpha-Hydroxylase and the action of vitamin D.

Hewison M, Zehnder D, Bland R, Stewart PM.

J Mol Endocrinol. 2000 Oct;25(2):141-8. Review.

9.

Renal osteodystrophy in dialysis patients: diagnosis and treatment.

Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.

Artif Organs. 1998 Jul;22(7):530-57. Review.

PMID:
9684690
10.

Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.

Sprague SM, Coyne D.

Clin J Am Soc Nephrol. 2010 Mar;5(3):512-8. doi: 10.2215/CJN.03850609. Epub 2010 Feb 4. Review.

11.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
12.

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.

Cheng S, Coyne D.

Expert Opin Pharmacother. 2006 Apr;7(5):617-21. Review.

PMID:
16553577
13.

Vitamin D analogues for secondary hyperparathyroidism.

Brown AJ, Dusso AS, Slatopolsky E.

Nephrol Dial Transplant. 2002;17 Suppl 10:10-9. Review.

14.

New vitamin D analogs.

Slatopolsky E, Finch J, Brown A.

Kidney Int Suppl. 2003 Jun;(85):S83-7. Review.

15.

Genetic disorders and defects in vitamin d action.

Malloy PJ, Feldman D.

Endocrinol Metab Clin North Am. 2010 Jun;39(2):333-46, table of contents. doi: 10.1016/j.ecl.2010.02.004. Review.

16.

Clinical uses of 1-alpha-hydroxy-ergocalciferol.

Park J, Rhee CM, Lau WL, Kalantar-Zadeh K.

Curr Vasc Pharmacol. 2014 Mar;12(2):306-12. Review.

PMID:
23713877
17.

1 alpha-Hydroxy-vitamin D2: a new look at an 'old' compound.

Coburn JW, Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Knutson JC, Bishop CW.

Nephrol Dial Transplant. 1996;11 Suppl 3:153-7. Review.

PMID:
8840332
18.

Role of vitamin d receptor activators in cardio-renal syndromes.

Cozzolino M, Bruschetta E, Stucchi A, Ronco C, Cusi D.

Semin Nephrol. 2012 Jan;32(1):63-9. doi: 10.1016/j.semnephrol.2011.11.009. Review.

PMID:
22365164
19.

[Vitamin D in the etiopathogenesis of autoimmune thyroiditis].

Łacka K, Maciejewski A.

Pol Merkur Lekarski. 2013 May;34(203):281-5. Review. Polish.

PMID:
23894780
20.

Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review.

Kallas M, Green F, Hewison M, White C, Kline G.

J Clin Endocrinol Metab. 2010 Jul;95(7):3111-7. doi: 10.1210/jc.2009-2673. Epub 2010 Apr 28. Review.

PMID:
20427501
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk